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ABSTRACT
Background Liver fibrosis progresses to decompen-
sated liver cirrhosis, for which medical needs remain 
unmet. We recently developed IC-2, a small-molecule 
compound that suppresses Wnt/β-catenin signaling, 
and found that IC-2 also suppresses liver fibrosis. In 
this study, we performed three-step screening of newly 
synthesized IC-2 derivatives to identify other small-
molecule compounds that suppress liver fibrosis.
Methods The screening system consisted of three 
steps: a cell viability assay, a transcription factor 4 
(TCF4) reporter assay, and induction of α-smooth mus-
cle actin (α-SMA) and collagen 1α1 (Col1A1) expression 
in response to each compound. Screening using human 
LX-2 hepatic stellate cells (HSCs) was performed to 
target HSCs, which are the driver cells of liver fibrosis.
Results In the first step, since 9b and 9b-CONH2 at 
100 μM did not have any effects on cell viability, they 
were omitted in the next screening. Additionally, the 
conditions that led to > 40% inhibition of the controls 
were also excluded in subsequent screening. The second 
step was performed under 31 conditions for 19 small-
molecule compounds. Sixteen small-molecule com-
pounds caused significant reduction of TCF4 activity 
relative to that of 0.1% DMSO. Of the 16 compounds, 
the 10 showing the greatest suppression of TCF4 
activity were selected for the third step. Expressions 
of mRNA for α-SMA and Col1A1 were significantly 
reduced by seven and three small-molecule compounds, 
respectively. The greatest reductions in the α-SMA and 
Col1A1 mRNA expressions were observed in the cells 
treated with IC-2-F. Protein expressions of α-SMA and 
Col1A1 caused by IC-2-F were also comparable to those 
caused by IC-2.
Conclusion IC-2-F was identified as a novel deac-
tivating small-molecule compound for HSCs in vitro. 
These data suggest that IC-2-F is a promising medicine 
for liver fibrosis.
Key words deactivation; hepatic stellate cells; liver 
fibrosis; small-molecule compound
Liver fibrosis is caused by chronic infection with the 
hepatitis B virus or hepatitis C virus, alcohol intoxica-
tion, or non-alcoholic steatohepatitis.1 Progressive liver 
fibrosis leads to decompensated liver cirrhosis (LC), for 
which medical needs remain unmet, and results in > 1 
million deaths annually worldwide.2, 3 Therefore, there 
is a great need for development of a novel therapy for 
liver fibrosis.
Myofibroblasts are the driver of tissue fibrogenesis 
in multiple organs, including the liver.1 A myofibroblast 
is a fibroblast-like cell with contractile properties and is 
typically derived from hepatic stellate cells (HSCs) via 
activation.4 Activated HSCs produce a large amount of 
collagen types I and III, which constitute fibrous tissues 
of pathological liver fibrosis.5 Several paracrine factors, 
such as platelet-derived growth factor (PDGF), trans-
forming growth factor-β (TGF-β), and connective tissue 
growth factor (CTGF) activate HSCs and maintain its 
activated state. Thus, since activation of HSCs is the 
major mechanism of liver fibrosis, the target of therapy 
for liver fibrosis proves to be HSCs.
Wnt/β-catenin signaling is upregulated in activated 
HSCs.6 The crosstalk between Wnt/β-catenin and 
TGF-β signaling highlights the role of Wnt/β-catenin 
signaling in liver fibrosis. Importantly, Wnt antagonism 
inhibits HSCs activation and liver fibrosis.7, 8 These data 
suggest that development of small-molecule compounds 
to target the Wnt/β-catenin pathway is an intriguing 
strategy for therapy of liver fibrosis.
We previously reported that genes downstream of 
Wnt/β-catenin signaling are downregulated during he-
patic differentiation of human mesenchymal stem cells9 
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and that suppression of Wnt/β-catenin signaling causes 
hepatic differentiation of human mesenchymal stem 
cells.10 Indeed, it has been demonstrated that mesen-
chymal stem cell sheets engineered by a Wnt/β-catenin 
signal inhibitor accelerated liver regeneration in mice.11 
Furthermore, we identified IC-2, a derivative of ICG-
001, as a potent inhibitor of Wnt/β-catenin signaling 
in human mesenchymal stem cells.12 Transplantation 
of IC-2-engineered cell sheets potently improved 
acute liver injury and reversed liver fibrosis.13, 14 We 
also found that IC-2 suppressed cancer stem cells of 
hepatocellular carcinoma (HCC) and colon cancer, 
respectively.15, 16 Taken together, drug discovery for 
liver fibrosis is promising when IC-2 is used as a leading 
small-molecule compound.
We previously found that IC-2 suppressed liver 
fibrosis.17 In the present study, 21 newly synthesized 
derivatives of IC-2 were screened in three steps: a cell 
viability assay, a transcription factor 4 (TCF4) reporter 
assay, and induction of α-smooth muscle actin (α-SMA) 
and collagen 1α1 (Col1A1) expression of human LX-2 
HSCs in response to each compound. Commonly, 
α-SMA and Col1A1 are used as markers of HSC activa-
tion and fibrogenesis, respectively.
In this study, our screening system consisted of 
three steps: a cell viability assay, a TCF4 reporter assay, 
and induction of α-SMA and Col1A1 expression in re-
sponse to each compound. We performed the screening 
on the basis of the following concept. Since HSCs play 
important roles in maintenance of liver functions, it may 
be harmful to pick up toxic small-molecule compounds 
to kill many HSCs in a cell viability assay. To obtain 
enough effects without any side effects on liver function, 
it seems to be required to keep a constant level of HSCs 
even after using the small-molecule compound as a 
medicine. To accomplish this purpose, we set a selection 
standard at around 40% reduction of a cell viability in 
the first step of screening. In this study, we tried to pick 
up the small-molecule compounds that display higher 
suppression of Wnt/β-catenin signaling without killing 
over 40% cells.
MATERIALS AND METHODS
Cells, IC-2 derivatives, and cell viability
The LX-2 HSC cell line was used for the experiments 
in this study.18 To identify potent deactivating small-
molecule compounds for HSCs, 21 newly developed 
derivatives of IC-2 were screened. All of the small-mol-
ecule compounds were produced in house. The newly 
developed small-molecule compounds, the original par-
ent compound IC-2, and their structures are shown in 
Fig. 1. The introduced groups such as OPMB, OMOM, 
MOTBS, and MOTBS mean O-methoxybenzyl, 
O-methoxymethyl, O-methoxymethyl, and methyl-O-
t-butyldimethylsilyl, respectively. At 24 h after plating, 
the LX-2 cells were treated with each compound at six 
different concentrations in Dulbecco’s Modified Eagle’s 
Medium containing 1% fetal bovine serum. Cell vi-
ability was measured by a water-soluble tetrazolium salt 
(WST) assay by using a Cell Counting Kit-8 (Dojindo 
Laboratories, Kumamoto, Japan) at 24 and 48 h after 
treatment.
Reporter assay
At 20 h after seeding, TCF4-CMVpro-GL4.20 and 
pRL-TK (Promega Corp., Fitchburg, WI) were co-
transfected into the LX-2 cells by using Lipofectamine 
2000 reagent (Invitrogen, Thermo Fisher Scientific Inc., 
Waltham, MA).9, 10, 12 TCF4-CMVpro-GL4.20 was de-
veloped as a TCF-4 motif-responsive luciferase reporter 
gene.12 In brief, three copies of the optimal TCF-4 motif 
CCTTTGATC and cytomegalovirus (CMV) promoter 
into the multiple cloning site of the pGL4.20 luciferase 
reporter plasmid (Promega Corp., Fitchburg, WI), 
subsequently designated pTCF-CMVpro-GL4.20. This 
plasmid is sensitive reporter plasmid to assess Wnt/
β-catenin signals.
At 4 h after transfection, the cells were treated with 
each compound at certain concentrations. Luciferase 
activities were determined after 48 h treatment by using 
the Dual-Luciferase Reporter Assay System (Promega) 
and MiniLumat LB 9506 (Berthold GmbH & Co. KG, 
Bad Wildbad, Germany). Luciferase activities were 
normalized to Renilla luciferase activity and expressed 
as percentages of the control.
Real-time quantitative polymerase chain reaction 
(qPCR)
LX-2 cells were treated with 2.5 ng/mL recombinant 
human TGF-β (R&D Systems, Inc., Minneapolis, 
MN) to convert the LX-2 cells to fibrogenic HSCs. At 
24 h after treatment, total RNA was extracted using 
RNeasy Plus Mini Kit (QIAGEN GmbH, Hilden, 
Germany) and reverse-transcribed with SSII RTase 
transcriptase (Invitrogen, Thermo Fisher Scientific 
Inc.). Real-time qPCR analysis was performed by using 
THUNDERBIRD SYBR qPCR Mix (Toyobo Co., Ltd., 
Osaka, Japan). The primer sets included α-SMA (for-
ward: 5’-CTG TTC CAG CCA TCC TTC AT-3’, reverse: 
5’-CCG TGA TCT CCT TCT GCA TT-3’), COL1A1 
(forward: 5’-CCT CCA GGG CTC CAA CGA G-3’, 
reverse: 5’-TCA ATC ACT GTC TTG CCC CA-3’), and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(forward: 5’-AGC CAC ATC GCT CAG ACA C-3’, 
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Fig. 1. Chemical structures of IC-2 and newly synthesized IC-2 derivatives.
A, IC-2-OMe (methoxy); B, IC-2-F; C, IC-2-Cl; D, IC-2-NO2; E, IC-2-OPMB (O-methoxybenzyl); F, IC-2-OMOM (O-methoxymethyl); 
G, IC-2-OTBS (O-t-butyldimethylsilyl); H, IC-2-OH; I, IC-2-MOTBS (methyl-O-t-butyldimethylsilyl); J, IC-2-MOH (hydroxymethyl); 
K, IC-2-Ar-OMe; L, IC-2-Ar-F; M, IC-2-Ar-Cl; N, IC-2-Ar-NO2; O, IC-2-Ar-OH; P, IC-2-506-1; Q, IC-2-506-2; R, IC-2-506-3; S, 9b; 
T, 9b-CONH2; U, 7c-NT; and V, IC-2.
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reverse: 5’-GCC CAA TAC GAC CAA ATC C-3’).
Western blot analysis
Twenty micrograms of protein from cells separated by 
sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis was transferred onto an Immobilon-P PVDF 
membrane. The primary antibodies for detection of 
α-SMA, COL1A1, and GAPDH included M0851 (Dako), 
sc-293182 (Santa Cruz), and MAB374 (Merck), respec-
tively. Secondary antibody was anti-mouse immuno-
globulin G horseradish peroxidase-linked whole Ab 
from sheep (GE Healthcare UK Ltd., Buckinghamshire, 
England). Signals were detected by a chemilumines-
cent image analyzer ChemiDoc Touch MP (Bio-Rad 
Laboratories Inc., Hercules, CA) using ECL Prime 
Western Blotting Detection Reagent (GE Healthcare).
Statistical analysis
Statistical analysis was performed by performing one-
way ANOVA followed by the Tukey HSD test. All 
statistical testing was performed by using IBM SPSS 
Statistics software Ver. 23.0.0.0 (IBM Corp., Armonk, 
NY). P-values < 0.05 were considered to be indicative 
of statistical significance.
RESULTS
First-step screening that selected 19 small-molecule 
compounds
For screening of 21 derivatives of IC-2, cell viabilities 
were first assessed at 24 and 48 h after incubation 
with each compound at six different concentrations 
per compound (Fig. 2). The conditions that exhibited 
> 40% inhibition of the controls were excluded from 
subsequent screening. In the first step of screening, 9b 
and 9b-CONH2 were excluded, since we can not expect 
that these compounds suppress Wnt/β-catenin signaling 
at the concentrations where cell viability is hardly af-
fected. The first screening selected 31 conditions from 
19 small-molecule compounds.
Second-step screening that selected 11 small-
molecule compounds
The TCF4 reporter assay was performed with 31 condi-
tions from 19 compounds in addition to 20 μM IC-2 and 
0.1% dimethyl sulfoxide (DMSO) as a control (Fig. 3A). 
Of the 31 conditions, 21 showed significant reduction 
of TCF4 activity in the TCF4 reporter assay relative to 
that for 0.1% DMSO (P < 0.01, each). The 21 conditions 
included 20 and 50 μM IC-2-OMe, 20 and 30 μM IC-
2-F, 6 μM IC-2-Cl, 30 and 50 μM IC-2-NO2, 50 μM IC-
2-OPMB, 25 and 30 μM IC-2-OMOM, 6 and 10 μM 
IC-2-OTBS, 30 μM IC-2-OH, 50 μM IC-2-Ar-OMe, 50 
μM IC-2-Ar-F, 50 μM IC-2-Ar-NO2, 50 μM IC-2-Ar-
OH, 5 μM IC-2-506-1, 20 μM IC-2-506-2, 10 μM IC-2-
506-3, and 10 μM 7c-NT. Twenty micromolar IC-2 gave 
about 50% TCF4 reporter activity relative to that of 0.1% 
DMSO as a positive control. However, 15 compounds 
including IC-2-OMe, IC-2-F, IC-2-NO2, IC-2-OPMB, 
IC-2-OMOM, IC-2-OTBS, IC-2-OH, IC-2-Ar-OMe, IC-
2-Ar-F, IC-2-NO2, IC-2-Ar-OH, IC-2-506-1, IC-2-506-
2, IC-2-506-3, and 7c-NT exhibited <40% activity. In 
particular, 11 compounds such as IC-2-F, IC-2-NO2, IC-
2-OPMB, IC-2-OMOM, IC-2-OTBS, IC-2-Ar-OMe, IC-
2-Ar-F, IC-506-1, IC-2-506-2, IC-2-506-3, and 7c-NT 
exhibited < 30% activities. The second step screening 
selected 11 small-molecule compounds for further 
screening.
Third screening that identified IC-2-F as a potent 
deactivating small-molecule compound for fibro-
genic hepatic stellate cells
Of 11 compounds that selected in the second screening, 
nine small-molecule compounds, i.e., IC-2-OMe, IC-
2-F, IC-2-Cl, IC-2-OPMB, IC-2-OTBS, IC-2-506-1, IC-
2-506-2, IC-2-506-3, and 7c-NT, were selected due to 
the intensity of suppression on the TCF4 reporter assay 
and the concentration < 20 μM, that is the concentra-
tion of IC-2. The third screening included the effects 
of these compounds on mRNA expressions of α-SMA 
and COL1A1. Of note, α-SMA was used because a 
heterogeneous population of α-SMA-positive cells, 
defined as hepatic myofibroblasts, have been found to 
have a major pro-fibrogenic role in the process of liver 
fibrosis.19 IC-2 caused an approximately 60% reduction 
in α-SMA mRNA relative to that of the 0.1% DMSO 
control. In addition to IC-2, six compounds, i.e., IC-2-
OMe, IC-2-F, IC-2-Cl, IC-2-OPMB, IC-2-506-2, and IC-
2-506-3, significantly suppressed expression of α-SMA 
mRNA relative to that of 0.1% DMSO (P < 0.01 for IC-
2-OMe, IC-2-F, IC-2-Cl, and IC-2-506-2, P < 0.05 for 
IC-2-OPMB and IC-506-3) (Fig. 3B). IC-2-F showed the 
greatest suppression among the six compounds. Among 
all nine compounds, IC-2-OMe and IC-2-F significantly 
suppressed expression of COL1A1 mRNA (Fig. 3C). 
IC-2-F also caused the most potent suppression of 
COL1A1 mRNA among nine compounds (Fig. 3C). 
These results indicated that IC-2-F was the strongest 
inhibitor of α-SMA and COL1A1. Western blot analysis 
showed that IC-2-F inhibited the expressions of α-SMA 
and COL1A1 to a degree similar to that of IC-2 (Fig. 
4). Taken together, these data suggested that IC-2-F is a 
novel deactivating small-molecule compound for HSCs 
in vitro and is a promising medicine for suppressing 
liver fibrosis.
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Fig. 2. Cell viability assay for various concentrations of small-molecule compounds. The effect of each small-molecule compound on 
cell viability was determined by a water-soluble tetrazolium salt assay at 24 and 48 h after addition of compound.
A, IC-2-OMe; B, IC-2-F; C, IC-2-Cl; D, IC-2-NO2; E, IC-2-OPMB; F, IC-2-OMOM; G, IC-2-OTBS; H, IC-2-OH; I, IC-2-MOTBS; J, IC-
2-MOH; K, IC-2-Ar-OMe; L, IC-2-Ar-F; M, IC-2-Ar-Cl; N, IC-2-Ar-NO2; O, IC-2-Ar-OH; P, IC-2-506-1; Q, IC-2-506-2; R, IC-2-506-3; S, 
9b; T, 9b-CONH2; and U, 7c-NT. All data are shown as the mean ± SD (n = 3).
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Fig. 3. Small-molecule compounds that inhibit TCF4/β-catenin transcriptional activity and expressions of α-SMA and Col1A1.
A. The effect of small-molecule compounds on Wnt/β-catenin signal activity in the human LX-2 hepatic stellate cell (HSC) line. TCF4/
β-catenin transcriptional activity is examined by dual-luciferase reporter assay in LX-2 cells treated with several concentrations for 48 h. 
The values of the 0.1% DMSO-treated cells are the controls, and the values obtained for each condition are expressed as a percentage of 
the control.
B. The effects of small-molecule compounds on HSC activation are shown. α-SMA mRNA expressions in LX-2 cells treated for 48 h as 
analyzed by qRT-PCR. Each expression level is normalized to GAPDH. All data are shown as the mean ± SD (n = 3). IC-2 is the positive 
control. One-way ANOVA followed by Tukey’s HSD test were performed. *P < 0.05, **P < 0.01 compared with 0.1% DMSO.
C. The effects of small-molecule compounds on collagen synthesis. Col1A1 mRNA expression in LX-2 cells treated for 48 hours as 
analyzed by qRT-PCR. Each expression level is normalized to GAPDH. All data are shown as the mean ± SD (n = 3). IC-2 is the positive 
control. One-way ANOVA followed by Tukey’s HSD test were performed. *P < 0.05, **P < 0.01 compared with 0.1% DMSO.
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DISCUSSION
Liver fibrosis leads to decompensated LC, which is 
associated with the complications of functional liver 
failure, portal hypertension, and hepatic encephalopa-
thy.1 In addition, HCC occurs in some patients with LC. 
Since approved therapies targeting liver fibrosis and LC 
are lacking, development of new therapies to regress 
liver fibrosis are urgently needed.
Myofibroblasts are the driver cells of liver 
fibrosis.1, 4 HSCs are the major precursors of myofi-
broblasts, and activation of HSCs promotes conversion 
to myofibroblasts. Several external stimuli, including 
hepatocellular cell death due to immune reaction, viral 
infection, oxidative stress, apoptosis, and cytokines, 
cause activation of HSCs.1, 4, 20 These reports suggest 
that anti-fibrotic therapies are supposed to include 
removal of external stimuli and/or direct deactivation of 
HSCs. Current treatments for chronic viral hepatitis are 
included in the former category, and those in the latter 
category await development.
Molecular dysregulation in activated HSCs/
myofibroblasts includes membrane signaling pathways, 
such as those involving TGF-β, PDGF, CTGF, Wnt/
β-catenin, and hedgehog signaling.1 Especially, TGF-β 
signaling has a major role in promoting liver fibrosis. 
Recent studies have reported that Wnt/β-catenin signal-
ing has an essential role in liver fibrosis.6 Crosstalk 
between Wnt/β-catenin and TGF-β signaling has been 
previously demonstrated.7, 8 Wnt/β-catenin signaling 
works in a combinatorial manner with TGF-β signaling. 
In contrast, suppression of Wnt/β-catenin signaling 
downregulates TGF-β signaling. Indeed, the molecular 
mechanism of the interactions between the β-catenin 
and TGF-β signaling pathways has been clarified.21 
Thus, suppression of Wnt/β-catenin signaling is a rea-
sonable therapeutic approach for liver fibrosis.
In our previous study, we confirmed that addition 
of Wnt3a caused a slight increase of Wnt/β-catenin 
signaling, however inhibitors of this pathway caused 
relatively large decrease in this signal intensity in LX-2 
cells.17 These data suggest that LX-2 cells displayed 
higher activities of Wnt/β-catenin signaling, and may 
imply that LX-2 cells are suitable for selection of sup-
pressors of Wnt/β-catenin signaling pathway.
In this study, although genetic controls were not 
employed, we previously confirmed Fzd8 siRNA 
potently suppressed the TCF4 activity.10 Therefore, to 
minimize technical errors, we used the values of the 0.1% 
DMSO-treated cells as the controls. This assay was sup-
ported by the character that LX-2 cells displayed higher 
activities of Wnt/β-catenin signaling.
Our screening was based on the concept that it 
is important to select small-molecule compounds that 
display higher suppressive activity on Wnt/β-catenin 
signaling within the concentrations exhibiting < 40% 
inhibition of the controls of cell viability. The small-
molecule compounds selected in this way are expected 
to have higher deactivating activity on HSCs, but have 
lower toxic side effects. HSCs play important roles 
in maintenance of liver functions since HSCs secrete 
several hepatotrophic factors.5 In this study, the reason 
why a cell viability assay on the basis of selecting the 
compounds exhibiting < 40% inhibition of the controls 
was due to this idea. Consequently, IC-2-F was selected 
as a promising medicine.
Activation or inactivation of Wnt/β-catenin signal 
Fig. 4. Western blot analysis of α-SMA and Col1A1 protein expressions after IC-2-F treatment. The LX-2 cells were cultured with 2.5 
ng TGF-β and 20 μM IC-2-F for the indicated hours. The α-SMA and Col1A1 protein levels determined by western blot analysis are 
shown. IC-2 is the positive control, and GAPDH is the internal control.
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is closely associated with subcellular distribution of 
β-catenin. β-catenin has dual roles, as an adhesion mol-
ecule at the plasma membrane and as an intermediate 
molecule in the canonical Wnt pathway. In our previous 
study, on activation of the Wnt signal, β-catenin translo-
cated into nucleus of UCBTERT-21 cells.10 On the other 
hand, when the Wnt/β-catenin signal was suppressed 
by transfection of Fzd8 siRNA, β-catenin was located 
along the cell membrane and in the cytoplasm of the 
cells. In this study, although subcellular localization of 
β-catenin was not examined, β-catenin was supposed 
to be localized on the plasma membrane and in the 
cytoplasm.
The mechanism that these IC-2 derivatives 
exhibit suppressive activity on Wnt/β-catenin signals 
in HSCs remains to be clarified. It has been reported 
that ICG-001 suppresses Wnt/β-catenin signals by 
binding CREB-binding protein (CBP).12 Since IC-2 is 
a derivative of ICG-001, IC-2 and IC-2 derivatives may 
interact with CBP. Further examination will be required 
to clarify the molecular mechanisms of IC-2 and IC-2 
derivatives on Wnt/β-catenin signals. In previous 
study, we found that hexachlorophene suppressed Wnt/
β-catenin signals in UE7T-13 human mesenchymal 
stem cells.11 Treatment with hexachlorophene led to 
reduction of β-catenin and cyclin D1, and the effect of 
hexachlorophene was abolished by MG-132, a protea-
some inhibitor. These data suggest that hexachlorophene 
suppressed Wnt/β-catenin signals via intracellular 
β-catenin degradation in proteasome. Furthermore, we 
found that HC-1, the derivative of hexachlorophene, 
has a different mechanism suppressing Wnt/β-catenin 
signals from hexachlorophene (data not shown). Thus, 
the small-molecule  compounds seem to have different 
mechanisms suppressing on Wnt/β-catenin signals even 
in their derivatives that have the similar structure with 
the original compounds.
We tried to explain the difference of biological 
activity from the viewpoint of the chemical structure 
of the compounds. For example, IC-2-OMe and IC-
2-F, whose substitution groups are OMe and F, had 
similar suppressive activities on Wnt/β-catenin signals. 
However, the electronegativity of OMe is the opposite 
of F. Furthermore, OMe and F also have different 
molecular size. It seemed to be difficult to explain the 
difference of suppressive effects on Wnt/β-catenin 
signals from a viewpoint of chemical structure of the 
compounds. Therefore, novel molecular designs may be 
required to clarify the structure-activity relationship.
In conclusion, we screened newly developed 
derivatives of IC-2 in three steps: a cell viability assay, 
a TCF4 reporter assay, and induction of α-SMA and 
Col1A1 expressions of human LX-2 HSCs in response 
to each compound. Consequently, we identified IC-
2-F as a novel deactivating small-molecule compound 
for HSCs in vitro. In this study, since the effect of IC-
2-F was examined at one dose, the dose-dependency 
and time-dependency on activation of HSCs and liver 
fibrosis are required in the near future. IC-2-F has 
more potent suppressive effects on a-SMA and Col1A1 
expression than IC-2 at mRNA level. Although in vivo 
study about IC-2-F will be required, it is expected that 
IC-2-F will a promising medicine for treatment of liver 
fibrosis.
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